Reovirus

Reoviruses, short for Respiratory Enteric Orphan viruses, are a family of double-stranded RNA viruses with potential applications in oncolytic virotherapy. One member of the Reoviridae family, the mammalian orthoreovirus type 3 (Reovirus serotype 3, Dearing strain), has shown promise in selectively targeting and destroying cancer cells. Research into oncolytic reoviruses involves exploiting their ability to replicate preferentially in cells with activated Ras signaling pathways commonly found in cancer cells. Preclinical and clinical studies have demonstrated the safety and efficacy of oncolytic reoviruses against a variety of cancers, including gliomas, breast cancer, and ovarian cancer. The virus induces cancer cell death while sparing normal cells, making it a potential therapeutic option. The mechanism of action involves both direct viral oncolysis and the stimulation of antitumor immune responses. Ongoing research aims to optimize the use of oncolytic reoviruses, exploring combination therapies with other cancer treatments and addressing challenges such as the development of neutralizing antibodies. The field of oncolytic virotherapy continues to evolve, and reoviruses hold promise as a novel and innovative approach to cancer treatment.